51788-80-8

Usage

Uses

4''-Fluoro-2''-methoxyacetophenone

Preparation

Preparation by reaction of methyl iodide with 4-fluoro-2-hydroxyacetophenone in the presence of potassium carbonate, ? in DMSO at r.t. for 1 h (100%); ? in acetone (97%).

InChI:InChI=1/C9H9FO2/c1-6(11)8-4-3-7(10)5-9(8)12-2/h3-5H,1-2H3

Upstream product

• 1481-27-2 4-Fluoro-2-hydroxyacetophenone 
• 74-88-4 methyl iodide 
• 456-49-5 1-fluoro-3-methoxybenzene 
• 108-24-7 acetic anhydride 
• 701-83-7 3-fluorophenyl acetate 
• 372-20-3 3-fluorophenol 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 93276-65-4 2'-methoxy-4'-methylthioacetophenone 
• 93276-66-5 α-bromo-2'-methoxy-4'-methylthioacetophenone 
• 102362-14-1 2-<2-methoxy-4-(methylsulfenyl)phenyl>imidazo<1,2-a>pyrazine 
• 114552-63-5 2-methoxy-4-(methylthio)-α-(trimethylsilyl)acetophenone 
• 93276-68-7 2-methoxy-4-(methylsulfonyl)acetophenone 
• 93276-69-8 α-bromo-2-methoxy-4-(methylsulfonyl)acetophenone 
• 114552-59-9 2-<2-methoxy-4-(methylthio)phenyl>imidazo<1,2-a>pyrazine 
• 114552-64-6 8-carbomethoxy-2-<2-methoxy-4-(methylthio)phenyl>imidazo<1,2-a>pyrazine 
• 93276-72-3 8-chloro-2-<2-methoxy-4-(methylsulfonyl)phenyl>imidazo<1,2-a>pyrazine hydrobromide 
• 114086-41-8 4-methanesulfonyl-2-methoxybenzoic acid 
• 108153-42-0 2-hydroxy-4-(methylsulfonyl)-2-nitrobenzoic acid 

Relevant academic research and scientific papers

Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors

Using reported glutathione S-transferase omega 1 (GSTO1-1) cocrystal structures, we designed and synthesized acrylamide-containing compounds that covalently bind to Cys32 on the catalytic site. Starting from a thiazole derivative 10 (GSTO1-1 IC50 = 0.6 μM), compound 18 was synthesized and cocrystallized with GSTO1. Modification on the amide moiety of hit compound 10 significantly increased the GSTO1-1 inhibitory potency. We solved the cocrystal structures of new derivatives, 37 and 44, bearing an amide side chain bound to GSTO1. These new structures showed a reorientation of the phenyl thiazole core of inhibitors, 37 and 44, when compared to 18. Guided by the cocrystal structure of GSTO1:44, analogue 49 was designed, resulting in the most potent GSTO1-1 inhibitor (IC50 = 0.22 ± 0.02 nM) known to date. We believe that our data will form the basis for future studies of developing GSTO1-1 as a new drug target for cancer therapy.

Identification of highly efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects

Synthesis and structure-activity relationship (SAR) of a series of nonsteroidal glucocorticoid receptor (GR) agonists are described. These compounds contain "diazaindole" moieties and display different transcriptional regulatory profiles in vitro and are

MODULATORS OF DOPAMINE NEUROTRANSMISSION

The present invention relates to novel1-(4H-1,3-benzodioxin-2-yl)methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically asdopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines

N-Aryloxylethylindolealkylamines (5) having dual 5-HT transporter and 5-HT1A affinity are described. These compounds represent truncated analogues of our previously reported piperidinyl derivatives (3). Compounds in this investigation were found to have more similar affinities and functional activities for the 5-HT1A receptor and 5-HT transporter. Though 5-HT1A antagonism is not consistently observed throughout series 5, several molecular features were found to be essential to obtain high and balanced activities. The proper placement of a heteroatom in the aryl ring and the length of the linkage used to tether the indole moiety had significant influence on 5-HT1A and 5-HT transporter affinities. Introduction of a halogen into the aryl ring usually lowered intrinsic activity and in some cases led to full 5-HT1A antagonists. Compounds 33 and 34 were observed to be full 5-HT1A antagonists with Ki values of approximately 30 nM for the 5-HT1A receptor and Ki values of 5 and 0.5 nM for the 5-HT transporter, respectively. Unfortunately, similar to our previous series (3), compounds in this report also had high affinity for the α1 receptor.

LiClO4-acyl anhydrides complexes as powerful acylating reagents of aromatic compounds in solvent free conditions

The Friedel-Crafts acylation of various activated benzenes is smoothly carried out with acyl anhydrides in the presence of 2 equiv. of LiClO4, as reaction promoter, under solventless conditions.

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues

The further development of allosteric HIV-1 RT inhibitors in the urea analogue series of PETT (phenylethylthiazolylthiourea) derivatives is described here. The series includes derivatives with an ethyl linker (1-5) and racemic (6-16) and enantiomeric (17-

Imidazopyrimidines and Imidazopyrazines: The Role of Nitrogen Position in Inotropic Activity

Congestive heart failure is a major medical problem for which existing medicaments have provided limited benefit.Recent new experimental drugs, including imidazo- and imidazopyridines, have both inotropic and vasodilatory properties.Subtle c

Inotropic agents

This invention provides for certain phenyl-substituted imidazo compounds, their pharmaceutical formulations, and their use as positive inotropic agents and vasodilators.